SkinBioTherapeutics plc (LON:SBTX – Get Free Report)’s share price traded up 14.1% during trading on Monday . The company traded as high as GBX 11 and last traded at GBX 10.84. Approximately 424,315 shares were traded during mid-day trading, a decline of 87% from the average session volume of 3,278,070 shares. The stock had previously closed at GBX 9.50.
SkinBioTherapeutics Stock Performance
The firm has a market cap of £31.41 million, a price-to-earnings ratio of -75.75 and a beta of 0.11. The stock has a 50-day moving average of GBX 9.96 and a 200-day moving average of GBX 11.72. The company has a debt-to-equity ratio of 11.77, a quick ratio of 10.01 and a current ratio of 6.14.
SkinBioTherapeutics (LON:SBTX – Get Free Report) last announced its quarterly earnings data on Monday, June 8th. The company reported GBX (0.31) EPS for the quarter. SkinBioTherapeutics had a negative return on equity of 5.25% and a negative net margin of 8.73%.The business had revenue of GBX 217 million during the quarter.
SkinBioTherapeutics Company Profile
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
Recommended Stories
- Five stocks we like better than SkinBioTherapeutics
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
